CER Daily Newsfeed

NPC Announces Takeda’s Jen Norton as Board Chair for 2025

(12/11, National Pharmaceutical Council Press Release) “...‘Jen’s deep expertise on the biopharmaceutical industry landscape has helped countless leaders better understand how this industry works and what levers will help patients access medicines,’ said John M. O’Brien, PharmD, MPH, NPC President and Chief Executive Officer. ‘She also understands the importance of timely, clear, policy-relevant research, which in 2025 will be more important than ever. I am grateful to her for her past leadership and excited for her continued leadership as Board Chair.’” Full

ISPOR Launches “HEOR Explained” Microsite

(12/10, ISPOR Press Release) “...‘HEOR Explained is an exciting new initiative designed to help anyone with an interest in healthcare to better understand how the field of HEOR can help improve healthcare decisions and the lives of patients,’ stated ISPOR CEO Rob Abbott. ‘As healthcare decision making becomes increasingly complex, HEOR insights can help cut through the noise to inform the best possible choices for patients. The HEOR Explained microsite, and initiatives like this, are in service of our vision of a world where healthcare is accessible, effective, efficient, and affordable for all.’” Full

New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLD

(12/11, Target RWE Press Release) “Target RWE, real-world evidence leader, shared two studies at The Liver Meeting 2024 that revealed insights on the NASH-CHECK1 patient-reported outcome measure (PROM) tailored for patients with metabolic dysfunction-associated steatotic liver disease (MASLD).” Full

Interprofessional George Mason Researchers Awarded More than $1 Million to Improve Outcomes for Patients with Depression

(12/10, George Mason University Press Release) “AI will soon receive a dose of empathy with the goal of helping to match people with depression to their best-fit medication. A team led by Farrokh Alemi, a professor in the College of Public Health, and Kevin Lybarger, an assistant professor in the College of Engineering and Computing, received $1,049,998 in research funding from the Patient-Centered Outcomes Research Institute to continue their work on developing an AI system that helps patients find the right depression medications.” Full

New Price Deal Paves Way for NICE Approval of Treatment for Rare Genetic Condition

(12/10, NICE Press Release) “Vamorolone (also called Agamree and made by Santhera), is an alternative to currently available corticosteroids used to reduce muscle inflammation and maintain muscle strength and function in people with DMD...New analysis presented by the company, together with an improved discount to the price of vamorolone, mean that NICE can now recommend it as a cost-effective use of NHS resources for people 4 years and over.” Full

Study Reveals Inequities and Inadequacies in Access to Medications and Treatment for Cardiovascular Conditions in Canada

(12/11, Elsevier) “...‘Can the Present Canadian Health Care System Provide Evidence-Based Pharmacare? Consideration of Two Important Cardiovascular Clinical Contexts’ compared all provincial drug formulary reimbursement criteria for medications recommended to treat heart failure with a reduced ejection fraction and antiplatelet therapies in acute coronary syndromes...The study assessed whether reimbursement criteria were concordant with listing recommendations from the Canadian Agency for Drugs and Technology in Health (CADTH) and with CCS cardiovascular therapy guidelines.” Full